A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

Author： Chu Franklin   Picus Joel   Fracasso Paula   Dreicer Robert   Lang Zhihui   Foster Brenda  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.4, 2011-08, pp. : 674-679

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William   Liu Glenn   Wilding George   Morris Thomas   Phung De   Dreicer Robert  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite

Prescribing of docetaxel for castrate-resistant prostate cancer has increased following publication of the TAX327 study and NICE recommendations

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 602, 2010-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

By Wissing Michel D   van Diest Paul J   van der Wall Elsken   Gelderblom Hans  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 5, 2013-06 ,pp. : 635-661

Informa Healthcare

Access to resources Recommend Favorite

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

By Schilling G.   Bruweleit M.   Harbeck N.   Thomssen C.   Becker K.   Hoffmann R.   Villena C.   Schütte M.   Hossfeld D.   Bokemeyer C.   Wit M.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 166-172

Springer Publishing Company

Access to resources Recommend Favorite

Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer: An Open-Label, Non-Comparative, Multicentre, Phase III Study

By Lundström Eija A.  

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 757-765

Adis International

Access to resources Recommend Favorite